The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase 2: Capecitabine (CAP) + oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA).
 
Peter C. Enzinger
Consulting or Advisory Role - Taiho Pharmaceutical
 
Thomas Adam Abrams
No Relationships to Disclose
 
Jennifer A. Chan
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Bayer (I); Pfizer (I); POZEN (I)
Research Funding - Novartis; Sanofi
 
Nadine Jackson McCleary
No Relationships to Disclose
 
Hui Zheng
No Relationships to Disclose
 
Eunice Lee Kwak
Travel, Accommodations, Expenses - Amgen; Pfizer
 
Matthew Yurgelun
Research Funding - Myriad Genetics
 
Lawrence Scott Blaszkowsky
No Relationships to Disclose
 
James M. Cleary
No Relationships to Disclose
 
Brian M. Wolpin
Consulting or Advisory Role - Genentech
 
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst)
 
Eileen Regan
No Relationships to Disclose
 
Christopher Graham
No Relationships to Disclose
 
Katharine Straw
No Relationships to Disclose
 
Charles S. Fuchs
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Celgene; Dicerna; Genentech/Roche; Gilead Sciences; Lilly; MedImmune; Merck; Momenta Pharmaceuticals; Pfizer; Pharmacyclics; POZEN; Sanofi; Takeda; Vertex
 
Ronan Joseph Kelly
Consulting or Advisory Role - Lilly; Novartis